°®¶¹´«Ã½










Abstract Submissions Are Closed

Join us in Long Beach, Calif. for a groundbreaking gathering of physicians, virology technicians and technologists, laboratory supervisors, laboratory directors and other health care professionals. Get your science in front of experts and peers at the annual gathering designed to discuss key viral infection topics—exploring the relationships between rapid viral diagnosis, clinical course of viral infections and preventive and therapeutic modalities for viral infections.

Late-breaking abstract submission closed Aug. 14. Keep an eye out—abstract dispositions will be sent on Aug. 22.



Submission Deadlines

April 17, 2024, 2 p.m. ET | Early Abstracts
June 20, 2024, 2 p.m. ET | General Abstracts, Travel Awards & Case Studies
Aug. 14, 2024, 2 p.m. ET | Late-Breaking Abstracts

A scientist points to a graph while discussing a poster with a colleague at ASM CVS.
Two scientists discuss a poster in the exhibit and poster hall at ASM CVS.

 

Case Study Submission Now Closed

The 2024 ASM Clinical Virology Symposium (CVS) also features case studies from participants. All participants are encouraged to submit case studies, although first preference will be given to medical technologists and trainees (e.g., students, pathology residents, infectious disease fellows) as an opportunity for them to receive some support to attend the meeting.

The ASM Program Committee will select up to 3 of the submitted cases for presentation at the 2024 ASM CVS program where the submitter will present their case to their peers. Individuals selected to present case studies will receive complimentary registration to the 2024 ASM Clinical Virology Symposium. The selection decision by the 2024 ASM CVS Program Committee is final and not subject to appeal.

Submitted cases must meet HIPPA requirements, including the removal of identifying information. Failure to do so will result in the submission’s disqualification.

The Case Study Submission Deadline was June 20, 2024, 2 p.m. ET. Submissions are now closed.

Twitter Feed